|Fastest Growing Market:||Asia-Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The contrast media market is projected to register a CAGR of 3.6% during the forecast period of 2022-2027.
The healthcare system has witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to reduce the risk of viral transmission, as most chronic pain therapies were regarded as non-urgent. Conversely, a chest CT scan is a prominent procedure used in the diagnosis of COVID-19. The first study on CT diagnosis of COVID-19 patients was published in the Lancet Journal in January 2020. Since then, the chest CT for pulmonary embolism has been increasingly used for a prognosis of the disease, as they are efficient in both alternative diagnoses and identifying complications of COVID-19. Thus, the market for contrast media is estimated to expand during the forecast period.
The major factors for the growth of the contrast media market include the increase in the incidences of chronic diseases, rising demand for image-guided procedures and diagnostics, and a large number of approvals for contrast agents. Image-guided procedures can help determine if a cancer is malignant or benign. With the increased prevalence and the increase in the number of cancer cases in both developing and developed economies of the world, it is necessary to provide procedures that can help patients get a diagnosis at the earlier stages.
The demand for diagnostics imaging is at an all-time high, with multiple types of chronic diseases prevalent globally. According to a report by the Medicare Payment Advisory Commission (MedPAC) to the Center for Medicare and Medicaid Services (CMS), the rise in the volume of imaging services per medicare beneficiary is the highest among all other services provided by physicians.
Image-guided surgeries (IGS) are gaining acceptance with time. These procedures are useful for diagnosis as well as treatment of multiple conditions. The rising need and demand for refinement of imaging during surgeries requires unique methods of data acquisition, processing, display, and a full understanding of the process of imaging and its applications in therapy. This need is very well served by image-guided procedures, and it has resulted in an increased demand for image-guided procedures for diagnostics and treatment, and hence, has served as a factor for market growth.
Scope of the Report
As per the scope of the report, contrast media is a substance used to enhance the contrast of an image and thus, make the image more detailed and clearer. Contrast media is increasingly being used in various medical imaging techniques, such as MRI and CT. The contrast media market is segmented by type (iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, and barium-based contrast media), procedure (x-ray/computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound), indication (cardiovascular disease, oncology, gastrointestinal disorders, neurological disorders, and other indications), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values (in USD million) for the above segments.
|Iodinated Contrast Media|
|Gadolinium-based Contrast Media|
|Microbubble Contrast Media|
|Barium-based Contrast Media|
|X-ray/Computed Tomography (CT)|
|Magnetic Resonance Imaging (MRI)|
Key Market Trends
Iodinated Contrast Media Segment Expected to Hold a Major Share in the Contrast Media Market
Iodinated contrast media is a form of intravenous radiocontrast (radiographic dye) containing iodine, which enhances the visibility of vascular structures and organs during radiographic procedures. The iodinated contrast has helped improve visibility in the diagnosis of diseases, such as cancer. The iodinated contrast media being used now are made up of the chemical modifications of the 2, 4, and 6 tri-iodinated benzene rings.
The ability of an iodinated contrast media to attenuate X-rays depends on the number of iodine molecules present in the tissue to be imaged and is inversely related to the X-ray energy used for imaging. Therefore, the type and amount of contrast media used for a given purpose also depend on the imaging characteristics needed. The segment is expected to grow in the future due to the increasing usage of ionic contrast media.
To understand key trends, Download Sample Report
North America Expected to Continue Market Dominance over the Forecast Period
North America holds a major share in the contrast media market and is expected to show a similar trend over the forecast period without significant fluctuations. The first gadolinium-based contrast agent was approved in the United States. Four agents were approved in the United States in the past decade, and this has resulted in a strong trend in the industry to continue to find more efficient, more accurate, and safe agents. The contrast media sales are expected to grow in the United States over the coming years. Among the different imaging modalities, sales of contrast media for the ultrasound market are expected to have a high growth rate. The United States is the largest consumer market for contrast media in North America. An increase in chronic diseases, such as cardiovascular and neurological diseases, is the major driving factor for the market’s growth in the United States.
To understand geography trends, Download Sample Report
The contrast media market is consolidated owing to the presence of a few major players. In terms of market share, a few of the major players are currently dominating the market. Some companies currently dominating the market include Bayer AG, Bracco Diagnostic Inc., GE Healthcare, Guerbet Group, Jodas Expoim, Lantheus Medical Imaging Inc., Spago Nanomedical AB, FUJIFILM Corporation, Beijing Beilu Pharmaceutical Co. Ltd, and Taejoon Pharm.
· In February 2022, Beijing Beilu Pharmaceutical’s Lopamidal passed the Consistency Evaluation for generic drugs. The evaluation helps in reviewing the quality and efficacy of generic drugs in comparison with the brand version of the drug.
· In July 2020, Bayer and Siemens Healthineers presented a new Imaging System Interface (ISI) for magnetic resonance imaging. The Interface combines MRXperion MR Injection System from Bayer and the Siemens Healthineers MR scanner in order to overcome the challenges faced by the conventional method.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in the Incidences of Chronic Diseases
4.2.2 Rising Demand for Image-guided Procedures and Diagnostics
4.2.3 Large Number of Approvals for Contrast Agents
4.3 Market Restraints
4.3.1 Side Effects and Allergic Reactions Associated with Contrast Agents
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type
5.1.1 Iodinated Contrast Media
5.1.2 Gadolinium-based Contrast Media
5.1.3 Microbubble Contrast Media
5.1.4 Barium-based Contrast Media
5.2 By Procedure
5.2.1 X-ray/Computed Tomography (CT)
5.2.2 Magnetic Resonance Imaging (MRI)
5.3 By Indication
5.3.1 Cardiovascular Disease
5.3.3 Gastrointestinal Disorders
5.3.4 Neurological Disorders
5.3.5 Other Indications
5.4.1 North America
126.96.36.199 United States
188.8.131.52 Rest of North America
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.4.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Bracco Diagnostic Inc.
6.1.3 GE Healthcare
6.1.4 Guerbet Group
6.1.5 Lantheus Medical Imaging Inc.
6.1.6 Spago Nanomedical AB
6.1.7 FUJIFILM Corporation
6.1.8 Beijing Beilu Pharmaceutical Co. Ltd
6.1.9 Taejoon Pharm
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Contrast Media Market market is studied from 2019 - 2027.
What is the growth rate of Contrast Media Market?
The Contrast Media Market is growing at a CAGR of 3.6% over the next 5 years.
Which region has highest growth rate in Contrast Media Market?
Asia-Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Contrast Media Market?
North America holds highest share in 2021.
Who are the key players in Contrast Media Market?
Bayer AG , Bracco Diagnostic Inc., GE Healthcare , Guerbet Group , Lantheus Medical Imaging Inc. are the major companies operating in Contrast Media Market.